Transplantation Clinical Trial
Official title:
A Randomized Controlled Trial Comparing Adjuvanted vs. Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients.
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for transplant patients, studies have shown that nonadjuvanted vaccine has poor immunogenicity. There are no studies that define the effect of adjuvanted vaccine in this population. The purpose of this study is to determine if a vaccination with FLUAD® results in improved immunogenicity as compared to standard vaccine in allo-HSCT recipients. Immunogenicity will be assessed by standard quantitative antibody titer assessments and using cell-mediated immunity measurements.
The investigators plan to study the immunogenicity of two different types of the influenza
vaccine in 240 allogeneic stem cell transplant patients during the 2015-2016 season.
Patients will be randomized to receive either adjuvanted influenza vaccine or nonadjuvanted.
Antibody titers will be evaluated by a standard hemagglutination inhibition assay. The
investigators hypothesize that the patients who receive the adjuvanted influenza vaccine
will reach significantly higher response to the vaccine. This study advances research on the
prevention of serious viral infections in transplant recipients.
Results from this study have the potential to directly improve patient care. If the use of
the adjuvanted influenza vaccine is successful, this strategy may lead to a significant
reduction in burden of disease, hospitalizations, and long-term morbidity.
The co-administration of vaccine with an adjuvant is a potentially promising method of
boosting immunogenicity. Two adjuvants have been used in influenza vaccines: AS03 and MF59.
Both are oil-in-water emulsions. AS03 was used in the monovalent pandemic A/H1N1 vaccine in
Canada and Europe. Adjuvanted vaccines have been studied in the hematopoietic stem cell
transplant population with most studies done in using the AS03-adjuvanted pandemic vaccine.
MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people
≥65 years old. MF59-adjuvanted vaccines have not been well studied in hematopoietic stem
cell transplantation but could represent a significant advance if they show greater
immunogenicity than the standard non-adjuvanted influenza vaccine. Both FLUAD® and the
standard 2015-2016 nonadjuvanted vaccine will contain 15 microgram antigen from each strain
and will be injected in a standard dose (0.5 mL) in the deltoid muscle by trained personnel.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00838357 -
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
|
Phase 3 | |
Terminated |
NCT00778856 -
Hand Transplantation for the Reconstruction of Below the Elbow Amputations
|
N/A | |
Active, not recruiting |
NCT00166842 -
Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
|
Phase 4 | |
Recruiting |
NCT04257747 -
Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI
|
N/A | |
Active, not recruiting |
NCT01687192 -
Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.
|
Phase 2 | |
Completed |
NCT00951977 -
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
|
N/A | |
Completed |
NCT00384202 -
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients
|
Phase 3 | |
Completed |
NCT00384137 -
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients
|
Phase 3 | |
Completed |
NCT00235664 -
Prospective Study of Drug Resistant Pathogens Among Liver, Intestinal and Multivisceral Transplant Recipients
|
N/A | |
Completed |
NCT03533049 -
mHealth Family Self-Management
|
N/A | |
Completed |
NCT02826213 -
Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient
|
||
Completed |
NCT00170170 -
Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation
|
N/A | |
Recruiting |
NCT06367244 -
Transplant Wellness Program
|
N/A | |
Recruiting |
NCT06166186 -
Effect of Intraoperative Music on Inflammatory Response in Donor Hepatectomy
|
N/A | |
Recruiting |
NCT00493194 -
Fibrosis in Renal Allografts
|
Phase 4 | |
Completed |
NCT00297310 -
Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation
|
Phase 4 | |
Completed |
NCT01019811 -
Innervated Sensory Cross-Finger Flap
|
N/A | |
Completed |
NCT04376775 -
Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation
|
||
Active, not recruiting |
NCT00166816 -
The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients
|
Phase 4 | |
Recruiting |
NCT03920735 -
Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
|